ACCOUNT

SECTIONS

HOME
- Homepage
- This Just In
- Chats
- Weather
- Traffic
- Event Guide
- PG Store
- PGe
- Video
- Photos
- The Digs
- RSS Feeds
NEWS
- News Home
- COVID-19
- World
- Nation
- State
- Obituaries
- News Obituaries
- Politics
- Education
- Portfolio
- Science
- Health & Wellness
- Environment
- Aging Edge
- Transportation
- Faith & Religion
- Crimes & Courts
- Social Services
LOCAL
- Local Home
- Region
- City
- North
- East
- West
- South
- Washington
- Westmoreland
- The Neighborhood
- Obituaries
- Classifieds
- Legal Notices
- Real Estate
SPORTS
- Sports Home
- Steelers
- Penguins
- Pirates
- Sports Columns
- Gene Collier
- Ron Cook
- Joe Starkey
- Paul Zeise
- High School Sports
- College Sports
- Pitt
- Penn State
- WVU
- NCAA
- NFL
- MLB
- NBA
- NHL
- North Shore Drive Podcast
OPINION
A&E
- A&E Home
- Celebrities
- Movies
- TV & Radio
- Music
- Concert Listings
- Theatre & Dance
- Art & Architecture
- Books
- Events
LIFE
- Life Home
- Food
- Buying Here
- Homes & Gardens
- Style & Fashion
- Travel
- Restaurants
- Seen
- goodness
- Random Acts of Kindness
- Pets
- Beer Me
- Outdoors
- Holidays
BUSINESS

OTHER

CLASSIFIEDS

Recent Quotes

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

Taysha Gene Therapies, Inc. - Common Stock (NQ:TSHA)

4.720 UNCHANGED

Streaming Delayed Price Updated: 4:00 PM EST, Feb 3, 2026 Add to My Watchlist

Price and Volume

Detailed Quote

Volume	0
Open	4.720
Bid (Size)	4.470 (1,000)
Ask (Size)	4.750 (100)
Prev. Close	4.720
Today's Range	4.720 - 4.720
52wk Range	1.050 - 6.020
Shares Outstanding	64,465,037
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

Taysha Gene Therapies Inc (NASDAQ:TSHA) Stock Slumps on Q3 Revenue Miss Despite Key Regulatory Win for TSHA-102 ↗

November 04, 2025

Taysha Gene Therapies stock fell after Q3 results, with a revenue miss overshadowing positive FDA Breakthrough Therapy designation for its Rett syndrome drug.

Via Chartmill

Earnings Scheduled For November 4, 2025 ↗

November 04, 2025

Via Benzinga

Performance

YTD	-10.1%	-10.1%
1 Month	-3.5%	-3.5%
3 Month	+10.5%	+10.5%
6 Month	+72.3%	+72.3%
1 Year	+208.5%	+208.5%

More News

Olema Pharmaceuticals, Exelixis, Genmab And Other Big Stocks Moving Lower In Monday's Pre-Market Session ↗

October 20, 2025

Via Benzinga

Why Is Taysha Gene Therapies Stock Falling Friday? ↗

October 17, 2025

Via Benzinga

Taysha Gene Therapies Stock Soars To 3-Year High After FDA Boost — Wall Street Calls Rett Drug ‘Derisked’ And Ahead Of Rivals ↗

October 03, 2025

Via Stocktwits

What's Next: Taysha Gene Therapies's Earnings Preview ↗

August 11, 2025

Via Benzinga

Where Taysha Gene Therapies Stands With Analysts ↗

June 02, 2025

Via Benzinga

Healthcare Sector Shines Amidst Market Turbulence, Bolstering S&P 500 Resilience

October 02, 2025

Via MarketMinute

Demystifying Taysha Gene Therapies: Insights From 6 Analyst Reviews ↗

October 02, 2025

Via Benzinga

Discover the most active stocks in Thursday's session. ↗

October 02, 2025

Via Chartmill

12 Health Care Stocks Moving In Thursday's Intraday Session ↗

October 02, 2025

Via Benzinga

Here are the top movers in Thursday's session. ↗

October 02, 2025

Via Chartmill

Taysha Gene Therapies, Canaan, Ondas Holdings And Other Big Stocks Moving Higher On Thursday ↗

October 02, 2025

Via Benzinga

Taysha Gene Therapies Stock Soars After FDA Grants Breakthrough Therapy Designation To Gene Therapy ↗

October 02, 2025

Via Stocktwits

Which stocks are gapping on Thursday? ↗

October 02, 2025

Via Chartmill

Top 2 Health Care Stocks That May Keep You Up At Night This Month ↗

October 02, 2025

Via Benzinga

What's Driving the Market Sentiment Around Taysha Gene Therapies? ↗

September 18, 2025

Via Benzinga

Is Taysha Gene Therapies Gaining or Losing Market Support? ↗

August 25, 2025

Via Benzinga

A Glimpse Into The Expert Outlook On Taysha Gene Therapies Through 11 Analysts ↗

August 13, 2025

Via Benzinga

Beyond The Numbers: 10 Analysts Discuss Taysha Gene Therapies Stock ↗

July 01, 2025

Via Benzinga

Retail Buzz Surges Around Taysha Gene Therapies After Positive Rett Syndrome Trial Data ↗

June 03, 2025

Via Stocktwits

Why Is Taysha Gene Therapies Stock Trading Higher On Thursday? ↗

May 29, 2025

Via Benzinga

12 Health Care Stocks Moving In Thursday's Pre-Market Session ↗

May 29, 2025

Via Benzinga

Earnings Scheduled For August 12, 2025 ↗

August 12, 2025

Via Benzinga

12 Health Care Stocks Moving In Wednesday's After-Market Session ↗

May 28, 2025

Via Benzinga

Frequently Asked Questions

Is Taysha Gene Therapies, Inc. - Common Stock publicly traded?

Yes, Taysha Gene Therapies, Inc. - Common Stock is publicly traded.

What exchange does Taysha Gene Therapies, Inc. - Common Stock trade on?

Taysha Gene Therapies, Inc. - Common Stock trades on the Nasdaq Stock Market

What is the ticker symbol for Taysha Gene Therapies, Inc. - Common Stock?

The ticker symbol for Taysha Gene Therapies, Inc. - Common Stock is TSHA on the Nasdaq Stock Market

What is the current price of Taysha Gene Therapies, Inc. - Common Stock?

The current price of Taysha Gene Therapies, Inc. - Common Stock is 4.720

When was Taysha Gene Therapies, Inc. - Common Stock last traded?

The last trade of Taysha Gene Therapies, Inc. - Common Stock was at 02/03/26 04:00 PM ET

What is the market capitalization of Taysha Gene Therapies, Inc. - Common Stock?

The market capitalization of Taysha Gene Therapies, Inc. - Common Stock is 304.27M

How many shares of Taysha Gene Therapies, Inc. - Common Stock are outstanding?

Taysha Gene Therapies, Inc. - Common Stock has 304M shares outstanding.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.